Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pimavanserin Open-Label Extension in Alzheimer's Disease Agitation
NCT03118947Phase 2Completed
- Sponsor
- Acadia Pharmaceuticals
- Start
- Feb 2017
- Primary completion
- Feb 2019
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 2 trial of pimavanserin in Alzheimer's disease (AD), sponsored by Acadia Pharmaceuticals. Started Feb 2017; status: completed.
02
Drugs
pimavanserin
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03118947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03118947.